MET and breast carcinoma: Such a redundant signaling via amplified MET may participate in breast cancer malignant behaviors during the treatment with anti-Her-2 antibody, Trastuzumab (Herceptin®) [38], possibly due to association (and re-activation) of Her2 with amplified MET [39,40].